EBITDA has posted 2015 sales growth of 56% , to £37.8m ( $47.2m ), compared to 2017 numbers, which stood at £ 25 m. Gross profit for the company increased by 56% , to 25 . The company's board expects 2017 earnings before interest, taxes, depreciation and amortisation to be positive.
Sinclair Pharma has posted a financial year sales growth of 51%, to £37.8m ($47.2m), compared to 2015 numbers, which stood at £25m. Gross profit for the company increased by 56%, to £26.7m. The company's board expects 2017 earnings before interest, taxes, depreciation and amortisation to be positive.